Liberation Labs selects Indiana for first biomanufacture

RICHMOND, Indiana, Jan. 24, 2023 (GLOBE NEWSWIRE) — Liberation Laboratories, a manufacturer of large-scale precision fermentations, has signed a purchase agreement for the site of its first commercial-scale biomanufacturing facility. The new facility, which will have a 600,000 liter fermentation capacity with a fully dedicated downstream process (DSP), will be located at the Midwest Industrial Park in Richmond, Indiana. Commercial production is expected by the end of 2024.

Liberation Labs is focused on enabling the commercial availability of organic products that meet the growing demand from existing major CPG and ingredient brands, as well as the emerging generation of precision fermentation-focused startups. The new facility will be the first purpose-built, commercial-scale, precision fermentation facility in the United States. The company has completed front-end loading level 3 (FEL-3) engineering and has started placing orders for long-lead equipment and building up the operations team. Groundbreaking is expected this spring.

“The three things a biofactory like ours needs are sugar, energy and people – and Richmond, Indiana has them all,” said Mark Warner, co-founder and CEO of Liberation Labs. “While sugar and electricity are commodities, skilled manufacturing workers are not, which is why Richmond really stands out. We are grateful for the support the state and local community have given us, and we can’t wait to break ground.”

The new facility will be built on a 36-acre lot within Phase I of Richmond, Indiana’s 700-acre Midwest Industrial Park, owned and maintained by the City of Richmond in partnership with the Economic Development Corporation of Wayne County. Liberation Labs will be the 10thth to settle tenants in this established industrial park.

This location offers tremendous logistical opportunities for the company, including:

  • Shovel-ready site with the required usable capacity;
  • Proximity to Interstate 70, the Norfolk Southern main line and three regional airports for shipping and logistics;
  • proximity to low-cost carbon resources;
  • A significant percentage of the baseload power for the facility is clean solar energy;
  • Proximity to three major metropolitan areas, provision of sufficiently qualified workers.

Liberation Labs will benefit from several key incentives offered by Wayne County and the State of Indiana, including tax credits, grants, utility offsets, job-related incentives and land purchase discounts. The company expects to invest $115 million in the facility and plans to create an estimated 45 well-paying manufacturing jobs.

“Next-generation technology is critical to the future food security of people around the world, and I’m proud that Indiana is leading the way,” said Indiana Secretary of Commerce Brad Chambers. “We are excited to welcome Liberation Labs to our growing agrobioscience ecosystem. Liberation Labs will continue to enable companies to innovate while creating high-paying, quality career opportunities for Hoosiers.”

Liberation Labs will not only increase the overall offering of bio-based consumer products, but also manufacture them at a lower cost because they are manufactured and distributed in the United States. Today, most bioproduction capacity is in Europe, but production and shipping fees make sourcing from there unaffordable.

“Securing this partnership and investment from Liberation Labs is another milestone in our strong relationship with Governor Holcomb and the Indiana Economic Development Corporation,” said Dave Snow, Mayor of Richmond. “We are thrilled to bring the expertise of Liberation Labs to our industrial park. When a company of this caliber decides to invest in Richmond, it is undoubtedly a clear vote of confidence that we are moving in the right direction. With more jobs being created and such a strong business model, I am confident that this is the right start to a long and mutually successful relationship.”

About Liberation Labs
Liberation Labs is commercializing precision fermentation with a global network of purpose-built manufacturing facilities that will enable the next wave of biotechnology advances to produce bio-based consumer products at scale. We combine modern technology with purposeful design to provide reliable and cost-effective solutions that meet customer demands around the world. For more information, see

A photo accompanying this announcement is available at